UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer

British Journal of Cancer

Volumn 101, Issue 1, 2009, Pages 98-105

  Unoki, M ^a   Kelly, J D ^b   Neal, D E ^b   Ponder, B A J ^b   Nakamura, Y ^c   Hamamoto, R ^b,c  

^a INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Bladder cancer; Diagnosis and prognosis marker; TURBT; UHRF1; Upper tract transitional cell carcinoma

Indexed keywords

MOLECULAR MARKER; UBIQUITIN LIKE WITH PHD AND RING FINGER DOMAINS 1; UNCLASSIFIED DRUG; CCAAT ENHANCER BINDING PROTEIN; MESSENGER RNA; TUMOR MARKER; UHRF1 PROTEIN, HUMAN;

ARTICLE; BLADDER CARCINOMA; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER RISK; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; MALE; ONCOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION; URINE SEDIMENT; BIOSYNTHESIS; BLADDER TUMOR; GENETICS; KIDNEY TUMOR; METABOLISM; PATHOLOGY;

CCAAT-ENHANCER-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 67649859436     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605123     Document Type: Article

References (34)

1. Abbady AQ, Bronner C, Bathami K, Muller CD, Jeanblanc M, Mathieu E, Klein JP, Candolfi E, Mousli M (2005) TCR pathway involves ICBP90 gene down-regulation via E2F binding sites. Biochem Pharmacol 70: 570-579
2. Achour M, Jacq X, Ronde P, Alhosin M, Charlot C, Chataigneau T, Jeanblanc M, Macaluso M, Giordano A, Hughes AD, Schini-Kerth VB, Bronner C (2008) The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene 27: 2187-2197
3. Arima Y, Hirota T, Bronner C, Mousli M, Fujiwara T, Niwa S, Ishikawa H, Saya H (2004) Down-regulation of nuclear protein ICBP90 by p53/ p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells 9: 131- 142
4. Arita K, Ariyoshi M, Tochio H, Nakamura Y, Shirakawa M (2008) Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature 455: 818-821
5. Avvakumov GV, Walker JR, Xue S, Li Y, Duan S, Bronner C, Arrowsmith CH, Dhe-Paganon S (2008) Structural basis for recognition of hemi- methylated DNA by the SRA domain of human UHRF1. Nature 455: 822-825
6. Berggren P, Steineck G, Adolfsson J, Hansson J, Jansson O, Larsson P, Sandstedt B, Wijkstrom H, Hemminki K (2001) p53 mutations in urinary bladder cancer. Br J Cancer 84: 1505- 1511
7. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, Akada M, Sunamura M, Prime W, Campbell F, Brentnall TA, Costello E, Neoptolemos J, Lemoine NR (2005) Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 129: 1454-1463
8. Dey P (2004) Urinary markers of bladder carcinoma. Clin Chim Acta 340: 57-65
9. Grandinetti CA, Goldspiel BR (2007) Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 27: 1125- 1144
10. Hashimoto H, Horton JR, Zhang X, Bostick M, Jacobsen SE, Cheng X (2008) The SRA domain of UHRF1 flips 5-methylcytosine out of the DNA helix. Nature 455: 826-829
11. Hopfner R, Mousli M, Jeltsch JM, Voulgaris A, Lutz Y, Marin C, Bellocq JP, Oudet P, Bronner C (2000) ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase Ilalpha expression. Cancer Res 60: 121-128
12. Hussain SP, Harris CC (2000) Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens. Mutat Res 462: 311 - 322
13. Jeanblanc M, Mousli M, Hopfner R, Bathami K, Martinet N, Abbady AQ, Siffert JC, Mathieu E, Muller CD, Bronner C (2005) The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle. Oncogene 24: 7337-7345
14. Jenkins Y, Markovtsov V, Lang W, Sharma P, Pearsall D, Warner J, Franci C, Huang B, Huang J, Yam GC, Vistan JP, Pali E, Vialard J, Janicot M, Lorens JB, Payan DG, Hitoshi Y (2005) Critical role ofthe ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell 16: 5621-5629
15. Lopez-Beltran A (2008) Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol Suppl 218: 95 - 109
16. Lorenzato M, Caudroy S, Bronner C, Evrard G, Simon M, Durlach A, Birembaut P, Clavel C (2005) Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions? Hum Pathol 36: 1101-1107
17. Lorenzo Romero JG, Salinas Sanchez AS, Gimenez Bachs JM, Sanchez Sanchez F, Escribano Martinez J, Hernandez Millan IR, Segura Martin M, Virseda Rodriguez JA (2004) p53 Gene mutations in superficial bladder cancer. Urol Int 73: 212 - 218
18. Lutzeyer W, Rubben H, Dahm H (1982) Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 127: 250- 252
19. Mousli M, Hopfner R, Abbady AQ, Monte D, Jeanblanc M, Oudet P, Louis B, Bronner C (2003) ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br J Cancer 89: 120- 127
20. Oba-Shinjo SM, Bengtson MH, Winnischofer SM, Colin C, Vedoy CG, de Mendonca Z, Marie SK, Sogayar MC (2005) Identification of novel differentially expressed genes in human astrocytomas by cDNA representational difference analysis. Brain Res Mol Brain Res 140: 25 - 33
21. Olsburgh J, Harnden P, Weeks R, Smith B, Joyce A, Hall G, Poulsom R, Selby P, Southgate J (2003) Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol 199: 41 - 49
22. Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 166: 1611 - 1623
23. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global Cancer Statistics, 2002. CA-Cancer J Clin 55: 74- 108
24. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP (1990) Biology and management of bladder cancer. N Engl J Med 322: 1129- 1138
25. Shariat SF, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, Erdamar S, Nguyen C, Wheeler TM, Slawin KM (2003) Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res 63: 4662-4670
26. Sharif J, Muto M, Takebayashi S, Suetake I, Iwamatsu A, Endo TA, Shinga J, Mizutani-Koseki Y, Toyoda T, Okamura K, Tajima S, Mitsuya K, Okano M, Koseki H (2007) The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 450: 908 - 912
27. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG (2001) Radical cystectomy in the treatment of invasive bladder cancer: long- term results in 1,054 patients. J Clin Oncol 19: 666- 675
28. Takata R, Katagiri T, Kanehira M, Shuin T, Miki T, Namiki M, Kohri K, Tsunoda T, Fujioka T, Nakamura Y (2007) Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci 98: 113 - 117
29. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, Namiki M, Kohri K, Matsushita Y, Fujioka T, Nakamura Y (2005) Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11: 2625 - 2636
30. Tomasino RM, Morello V, Tralongo V, Nagar C, Nuara R, Daniele E, Curti M, Orestano F (1994) p53 expression in human renal cell carcinoma: an immunohistochemical study and a literature outline of the cytogenetic characterization. Pathologica 86: 227 - 233
31. Torti FM, Lum BL (1984) The biology and treatment of superficial bladder cancer. J Clin Oncol 2: 505 - 531
32. Unoki M, Nishidate T, Nakamura Y (2004) ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 23: 7601 - 7610
33. van Rhijn BW, van der Poel HG, van der Kwast TH (2005) Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47: 736- 748
34. Wallard MJ, Pennington CJ, Veerakumarasivam A, Burtt G, Mills IG, Warren A, Leung HY, Murphy G, Edwards DR, Neal DE, Kelly JD (2006) Comprehensive profiling and localisation of the matrix metalloprotei- nases in urothelial carcinoma. Br J Cancer 94: 569 - 577